

BIOTOSCANA INVESTMENTS S.A. Corporate Taxpayer's ID (CNPJ/MF): 19.688.956/0001-56 L-1470 Luxembourg, 70 route d'Esch, Grand-Duché de Luxembourg Legal representative in Brazil: Av. dos Imarés, 401, São Paulo, SP

NOTICE TO THE MARKET

BIOTOSCANA INVESTMENTS S.A. ("Company" or "GBT") (B3: GBIO33), pursuant to the provisions of CVM Instruction No. 358/2002, as amended, hereby announces to its shareholders and to the market in general that it has received correspondence stating that Fourth Sail Capital LP. ("Fourth Sail"), holds, as of December 27th, 2019, 5,331,200 Brazilian Depositary Receipts ("BDRs") issued by the Company.

The shareholding of these investors represents approximately 5.00% of the shares issued by GBT.

Montevideo, January 6th, 2020

BIOTOSCANA INVESTMENTS S.A.

Claudio Coracini Legal Representative in Brazil

About GBT Grupo Biotoscana

GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT's strong portfolio combines world-class licenses and proprietary products. To find out more, please visit <u>www.grupobiotoscana.com</u>.